benfotiamine / Generic mfg. - LARVOL DELTA

The MID1IP1/S100A10-mGluR5 Axis in Seizures: Immune-Metabolic Crosstalk and Enhanced Therapeutic Efficacy of Benfotiamine/Phenytoin Combination. (PubMed, Curr Neuropharmacol) - "The MID1IP1/S100A10-mGluR5 axis drives seizure pathogenesis through metabolic-immune crosstalk. BFT and PHT target complementary nodes of this pathway, demonstrating enhanced efficacy in preclinical models."

Journal • CNS Disorders • Epilepsy • MID1 • S100A10

Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P4 | N=66 | Recruiting | Sponsor: Thammasat University | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain

Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P4 | N=66 | Not yet recruiting | Sponsor: Thammasat University

New P4 trial • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain

Vitamin B Supplementation for Diabetic Peripheral Neuropathy: A Review and Meta-Analysis. (PubMed, J Clin Med) - "Sural nerve conduction velocity (MD 2.10 m/s, 95% CI 0.35 to 3.86) and amplitude (MD 0.88 µV, 95% CI 0.08 to 1.67) improved significantly...However, substantial heterogeneity and risk of bias preclude firm recommendations for routine use. Well-designed RCTs stratified by baseline vitamin status are needed."

Journal • Retrospective data • Review • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Peripheral Neuropathic Pain

Exploring the bioavailability and bioactivity of thiamine versus allithiamine: studies in Drosophila melanogaster and mice. (PubMed, Front Nutr) - "Flies were reared on a chemically defined, thiamine-free medium supplemented with thiamine, allithiamine or benfotiamine as a lipophilic reference compound...These results establish allithiamine as a biologically active thiamine vitamer in vivo. They further highlight post-translational regulation as a key mechanism governing metabolic adaptation to thiamine repletion with implications for nutrition research and the evaluation of thiamine vitamers in dietary strategies."

Journal • Preclinical • PDHA1

Bacopa-Enriched Formulation Enhances Memory and Synaptic Plasticity in a Rat Model of Vascular Dementia. (PubMed, Behav Brain Res) - "This study evaluated the effect of a Bacopa-enriched formulation (BEF) containing Bacopa monnieri, coenzyme Q10, acetyl-L-carnitine, phosphatidylserine, benfotiamine, and methyl folate in a rat 2-vessel occlusion (2VO) model of VD. Motor and exploratory functions remained largely unaffected. Findings from this study suggest BEF's memory enhancement is primarily mediated via modulation of excitatory neurotransmission, enhancement of neuroplasticity, and modification of cognitive function biomarkers, with minimal cholinergic system involvement."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Pain • BDNF

Efficacy and safety of benfotiamine in diabetic peripheral neuropathy: a systematic review and meta-analysis (CINP 2026) - "Current analyses suggests that benfotiamine is safe but does not statistically significant reduce pain and overall neuropathy symptom scores in DPN. However, the strength of the evidence is limited by the small number of included studies and substantial heterogeneity. While a potential benefit on sensory symptoms cannot be excluded, heterogeneity of outcome measures and limit sensitivity of commonly used symptom scales preclude definitive conclusions."

Late-breaking abstract • Retrospective data • Review • Diabetic Neuropathy • Peripheral Neuropathic Pain

Discovery of Benfotiamine as a subnanomolar P2Y14R antagonist for inflammatory diseases via drug repurposing and molecular dynamics-guided mechanism elucidation. (PubMed, Eur J Med Chem) - "Functionally, Benfotiamine exhibited therapeutic efficacy in murine models of dextran sulfate sodium-induced colitis and monosodium urate-induced gouty arthritis. Beyond presenting a promising repurposed anti-inflammatory agent, this study validates a modular and extensible computational-experimental integration platform that can be widely applied to expedite the discovery and mechanistic characterization of GPCR-targeted therapeutics."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) (clinicaltrials.gov) - P2 | N=406 | Active, not recruiting | Sponsor: Alzheimer's Disease Cooperative Study (ADCS) | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders

Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. (PubMed, Nutrients) - "Both agents target key pathways in DPN pathogenesis. ALA is the most established adjunctive metabolic therapy for symptomatic DPN, although no study has demonstrated structural nerve regeneration or a definitive disease-modifying effect. Benfotiamine is biologically plausible but requires further validation in long-term randomized trials with structural and biomarker-based endpoints. Outside of documented thiamine deficiency, its routine use cannot be recommended based on current evidence."

Journal • Review • Diabetes • Diabetic Neuropathy • Inflammation • Metabolic Disorders • Pain

Reduction of glycation stress as a geroscience intervention: protocol for a pilot RCT in postmenopausal women. (PubMed, NPJ Aging) - P=N/A | "Preclinical studies show that GLYLO, a five-compound glycation-lowering formulation (alpha-lipoic acid, nicotinamide, pyridoxine, benfotiamine, and piperine), reduces AGE burden and improves metabolic health, but its translational relevance in humans is unknown...GRACE is designed to address a critical gap in geroscience by evaluating whether targeting glycation can mitigate early metabolic and functional decline in postmenopausal women. ClinicalTrials.gov identifier NCT06813261."

Clinical • Journal • Inflammation • Metabolic Disorders • Obesity

Prevention of melanoma growth and invasion by lipophilic vitamin B1 derivatives (AAD 2026) - "Our data suggest that Benfotiamine and Fursultiamine effectively prevented melanoma cell growth in B16-F10 cells and prevented the invasion and migration of cancer cells. Our results suggest that lipophilic vitamin B1 derivatives prevent melanoma cell growth and invasion, indicating their chemopreventive effects."

Genetic Disorders • Melanoma • Skin Cancer • Solid Tumor

THIAMINE PYROPHOSPHOKINASE-1 INSUFFICIENCY CAUSING REDUCED THIAMINE DIPHOSPHATE IS CRUCIAL FOR THE PATHOGENESIS AND TREATMENT OF ALZHEIMER'S DISEASE (ADPD 2026) - "Insufficient TPK, thereby reducing TDP, plays key a role in the pathogenesis and treatment of AD. The interplay between TPK and amyloid-β represents a missing clue linking amyloid-β deposition to neurodegeneration. Combined with the positive results of the published clnical trials of benfotiamine, a derivative of thiamine, treating AD, the proof of concept of TPK/TDP as a therapeutic target for AD has been completed."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Huntington's Disease • Movement Disorders • Parkinson's Disease • CX3CR1 • SLC19A2

Benfotiamine promotes diabetic wound healing by modulating Trisk95 and reducing oxidative stress. (PubMed, Diabetol Metab Syndr) - No abstract available

Journal

WOE-DE-2023-2: Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial (ARIEL) (clinicaltrialsregister.eu) - P1/2 | N=136 | Not yet recruiting | Sponsor: Woerwag Pharma GmbH & Co. KG

New P1/2 trial • Diabetic Neuropathy • Pain • Severe Hypoglycemia

Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). (PubMed, BMJ Open Diabetes Res Care) - P2 | "In type 2 diabetes individuals with mild-to-moderate symptomatic DSPN, treatment with benfotiamine for 12 months was well tolerated, but had no significant effects on multiple morphometric, neurophysiological and clinical measures of neuropathy."

Biomarker • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Psychiatry • Type 2 Diabetes Mellitus

Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes. (PubMed, Front Pharmacol) - "Functionally, in 3T3-L1 adipocytes, thiamine induced adipogenesis and PPARγ-response element binding with a potency analogous to rosiglitazone, suggesting direct agonistic activity. Corroborating these mechanistic insights at the clinical level, a new meta-analysis of randomized controlled trials demonstrates that high-dose benfotiamine, a synthetic thiamine derivative, significantly improves neuropathic and vascular outcomes in T2D patients. While the contribution of thiamine's established antioxidant effects to these clinical benefits cannot be ruled out, the synergy of computational, cellular, and human evidence provides a compelling foundation for our hypothesis. This study suggests that thiamine could act as a PPARγ ligand and serve as a safer treatment option for metabolic disorders, which needs to be tested in vivo."

Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • PPARG

A Retrospective Study of the Association between Low Vitamin B1 in the Blood and Cognitive Impairment in Patients with Alzheimer's Disease. (PubMed, J Nutr Sci Vitaminol (Tokyo)) - "While benfotiamine, a lipid-soluble VB1 derivative, has been suggested to improve cognition, its causal effect remains uncertain due to the study's cross-sectional design. Selection bias and the lack of dietary data are also limitations. Further longitudinal research is needed to determine whether VB1 supplementation could help mitigate cognitive decline in AD patients."

Journal • Observational data • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Potential of Benfotiamine in the treatment of neuropsychological disorders. (PubMed, Mol Biol Rep) - "In this narrative review, we provide a comprehensive overview of the cellular and molecular pathways modulated by benfotiamine in the context of neuropsychiatric disorders. Specifically, we highlight its effects on oxidative stress, inflammatory signaling, mitochondrial function, glucose metabolism, and advanced glycation end-product (AGE) formation, all of which contribute to its neuroprotective and potentially therapeutic properties."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Mental Retardation • Psychiatry

Evaluation of the protective effect of Benfotiamine against neurotoxic effects, depression and oxidative stress induced by noise exposure. (PubMed, Sci Rep) - "Benfotiamine also appears to be more effective than N-acetylcysteine in reducing noise exposure effects. The findings confirm that noise contributes to oxidative stress in the brain and the development of depressive-like behaviors, while also highlighting the protective effects of Benfotiamine against noise-induced damage."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Thiamine Compounds Alleviate Oxidative Stress, Over-Expression of Pro-Inflammatory Markers and Behavioral Abnormalities in a Mouse Predation Model of PTSD. (PubMed, Int J Mol Sci) - "Treatment with thiamine or benfotiamine significantly ameliorated most of these changes in the stressed groups. Thus, thiamine compounds may have therapeutic potential in patients with PTSD, owing to their antioxidant and anti-inflammatory properties."

Biomarker • Journal • Preclinical • CNS Disorders • Inflammation • Mood Disorders • Pain • Post-traumatic Stress Disorder • Psychiatry • FOS • IL1B

Transketolase Activation Improves Fatty Liver Ischemia Reperfusion Injury by Inhibiting Ferroptosis via Ncoa4 Downregulation (WTC 2025) - "Further, TKT activation with benfotiamine could protect from hepatocytes injury in vivo and in vitro... TKT plays an important role in fatty liver IRI. TKT activation could primarily alleviating ferroptosis in fatty liver transplantation via inhibition of Ncoa4 expression."

Cardiovascular • Hepatology • Liver Failure • Reperfusion Injury • NCOA4

Protective effects of benfotiamine supplementation and aerobic training against noise-induced cardiovascular damage: A focus on oxidative stress and inflammatory pathways. (PubMed, Biochem Biophys Res Commun) - "Our findings suggest that BFT's antioxidant and anti-inflammatory properties, in combination with MICT as a non-pharmacological approach, may protect against noise-induced cardiovascular problems. BFT and MICT mitigate noise-induced cardiac injury via antioxidant and anti-inflammatory mechanisms, with additive benefits evident in the combined treatment group."

Journal • Cardiovascular • IL1B • IL6 • TNFA

Early diagnosis and effective therapy of diabetic polyneuropathy (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The pathogenetic therapy of DPN includes the use of alpha-lipoic acid and benfotiamine, the effectiveness of which has been shown in clinical studies. Adjuvant analgesics are used as symptomatic therapy, namely drugs from the group of antiepileptic drugs (gabapentin, pregabalin) and antidepressants (duloxetine). Doctors' knowledge of the problem of diagnosis and treatment of DPN will make it possible to detect this disease at an early stage and effectively control the progression of symptoms."

Journal • Review • Diabetes • Diabetic Neuropathy • Gene Therapies • Metabolic Disorders • Pain

Benfotiamine prevents endotoxin-induced cytotoxicity in human dermal fibroblasts (SID 2025) - "Future experiments will explore benfotiamine's effects on apoptotic signaling by examining caspase-3 activation, PARP cleavage, and the expression of apoptotic markers. Additional in-vivo studies are planned to determine the therapeutic potential of benfotiamine in improving wound healing."

Diabetes • Infectious Disease • Metabolic Disorders • CASP3